Farmorubicin; Pharmorubicin

SECTION 2: Hazards identification

Appearance: Red freeze-dried powder

Signal word

WARNING

Hazard statements

Suspected of causing cancer. Suspected of causing genetic defects.

Additional information

Short Term: Drugs of this class have been associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure. Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on testes the developing fetus. Known Clinical Effects: Adverse effects most commonly reported in clinical use include local irritation, nausea, vomiting, inflammation of the mouth (stomatitis), facial flushing, conjunctivitis of the eye, tearing (lachrymation), loss of hair, and discoloration of skin. Effects on blood and blood-forming organs have also occurred. EU Indication of danger: Carcinogenic: Category 2 Mutagenic: Category 2 EU Hazard Symbols: EU Risk Phrases: R45 - May cause cancer. R46 - May cause heritable genetic damage. Australian Hazard Classification

Hazardous Ingredients

Non-Dangerous Goods (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.